Omeros (OMER) Posts Earnings Results, Misses Estimates By $0.04 EPS

Omeros (NASDAQ:OMER) released its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.04), Fidelity Earnings reports. The company had revenue of $4.61 million for the quarter, compared to the consensus estimate of $3.07 million. During the same quarter in the prior year, the firm earned ($0.16) earnings per share.

OMER stock traded down $3.00 during mid-day trading on Friday, hitting $13.02. The company had a trading volume of 5,656,225 shares, compared to its average volume of 613,109. The firm has a market cap of $793.47 million, a price-to-earnings ratio of -16.48 and a beta of 3.79. Omeros has a 12 month low of $8.36 and a 12 month high of $27.00.

In other Omeros news, VP Marcia S. Kelbon sold 7,529 shares of Omeros stock in a transaction dated Friday, August 31st. The shares were sold at an average price of $25.75, for a total value of $193,871.75. Following the sale, the vice president now owns 227,645 shares of the company’s stock, valued at $5,861,858.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 12.10% of the company’s stock.

OMER has been the topic of a number of recent analyst reports. ValuEngine raised shares of Omeros from a “buy” rating to a “strong-buy” rating in a research report on Monday, September 24th. HC Wainwright set a $34.00 price target on shares of Omeros and gave the company a “buy” rating in a research report on Monday, October 15th. Wedbush set a $20.00 price target on shares of Omeros and gave the company a “hold” rating in a research report on Friday, August 10th. BidaskClub lowered shares of Omeros from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 6th. Finally, Zacks Investment Research raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Saturday, August 18th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $27.56.

TRADEMARK VIOLATION WARNING: This report was published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.com-unik.info/2018/11/10/omeros-omer-posts-earnings-results-misses-estimates-by-0-04-eps.html.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

See Also: Growth Stocks, What They Are, What They Are Not

Earnings History for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit